🚀 VC round data is live in beta, check it out!
Ever Supreme Bio Technology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ever Supreme Bio Technology and similar public comparables like PureTech Health, Vanda Pharmaceuticals, Autolus Therapeutics, Neurogene and more.
Ever Supreme Bio Technology Overview
About Ever Supreme Bio Technology
Ever Supreme Bio Technology Co Ltd is a Taiwan-based company. The company is engaged in research, development, and manufacturing of new drugs related to human mesenchymal stem cells and immune cells. The company operates in two segments: Cell Preparation Business Unit and Other Operating Business. The company gained a majority of revenue from the cell preparation Business, which is engaged in the research, development, manufacture, and sales of various new drugs and cell preparations, and investments related to biotechnology and medical industry businesses.
Founded
2016
HQ
Employees
99
Website
Financials (LTM)
EV
$419M
Ever Supreme Bio Technology Financials
Ever Supreme Bio Technology reported last 12-month revenue of $34M.
In the same LTM period, Ever Supreme Bio Technology generated $17M in net income.
Revenue (LTM)
Ever Supreme Bio Technology P&L
In the most recent fiscal year, Ever Supreme Bio Technology reported revenue of $33M and EBITDA of $17M.
Ever Supreme Bio Technology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $34M | XXX | $33M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $23M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 70% | XXX | XXX | XXX |
| EBITDA | — | XXX | $17M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 53% | XXX | XXX | XXX |
| EBIT Margin | 44% | XXX | 43% | XXX | XXX | XXX |
| Net Profit | $17M | XXX | $16M | XXX | XXX | XXX |
| Net Margin | 48% | XXX | 49% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ever Supreme Bio Technology Stock Performance
Ever Supreme Bio Technology has current market cap of $432M, and enterprise value of $419M.
Market Cap Evolution
Ever Supreme Bio Technology's stock price is $4.46.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $419M | $432M | 0.5% | XXX | XXX | XXX | $0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEver Supreme Bio Technology Valuation Multiples
Ever Supreme Bio Technology trades at 12.2x EV/Revenue multiple, and 24.0x EV/EBITDA.
EV / Revenue (LTM)
Ever Supreme Bio Technology Financial Valuation Multiples
As of April 19, 2026, Ever Supreme Bio Technology has market cap of $432M and EV of $419M.
Equity research analysts estimate Ever Supreme Bio Technology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ever Supreme Bio Technology has a P/E ratio of 26.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $432M | XXX | $432M | XXX | XXX | XXX |
| EV (current) | $419M | XXX | $419M | XXX | XXX | XXX |
| EV/Revenue | 12.2x | XXX | 12.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 24.0x | XXX | XXX | XXX |
| EV/EBIT | 27.7x | XXX | 29.8x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 18.3x | XXX | XXX | XXX |
| P/E | 26.0x | XXX | 27.1x | XXX | XXX | XXX |
| EV/FCF | (21.5x) | XXX | 24.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ever Supreme Bio Technology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ever Supreme Bio Technology Margins & Growth Rates
Ever Supreme Bio Technology's revenue in the last 12 month grew by 10%.
Ever Supreme Bio Technology's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Ever Supreme Bio Technology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 53% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 12% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ever Supreme Bio Technology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ever Supreme Bio Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| PureTech Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Vanda Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Autolus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Neurogene | XXX | XXX | XXX | XXX | XXX | XXX |
| Climb Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ever Supreme Bio Technology M&A Activity
Ever Supreme Bio Technology acquired XXX companies to date.
Last acquisition by Ever Supreme Bio Technology was on XXXXXXXX, XXXXX. Ever Supreme Bio Technology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ever Supreme Bio Technology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEver Supreme Bio Technology Investment Activity
Ever Supreme Bio Technology invested in XXX companies to date.
Ever Supreme Bio Technology made its latest investment on XXXXXXXX, XXXXX. Ever Supreme Bio Technology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ever Supreme Bio Technology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ever Supreme Bio Technology
| When was Ever Supreme Bio Technology founded? | Ever Supreme Bio Technology was founded in 2016. |
| Where is Ever Supreme Bio Technology headquartered? | Ever Supreme Bio Technology is headquartered in Taiwan. |
| How many employees does Ever Supreme Bio Technology have? | As of today, Ever Supreme Bio Technology has over 99 employees. |
| Is Ever Supreme Bio Technology publicly listed? | Yes, Ever Supreme Bio Technology is a public company listed on Taipei Exchange. |
| What is the stock symbol of Ever Supreme Bio Technology? | Ever Supreme Bio Technology trades under 6712 ticker. |
| When did Ever Supreme Bio Technology go public? | Ever Supreme Bio Technology went public in 2018. |
| Who are competitors of Ever Supreme Bio Technology? | Ever Supreme Bio Technology main competitors are PureTech Health, Vanda Pharmaceuticals, Autolus Therapeutics, Neurogene. |
| What is the current market cap of Ever Supreme Bio Technology? | Ever Supreme Bio Technology's current market cap is $432M. |
| What is the current revenue of Ever Supreme Bio Technology? | Ever Supreme Bio Technology's last 12 months revenue is $34M. |
| What is the current revenue growth of Ever Supreme Bio Technology? | Ever Supreme Bio Technology revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Ever Supreme Bio Technology? | Current revenue multiple of Ever Supreme Bio Technology is 12.2x. |
| Is Ever Supreme Bio Technology profitable? | Yes, Ever Supreme Bio Technology is net-income-positive (as of the last 12 months). |
| What is the current net income of Ever Supreme Bio Technology? | Ever Supreme Bio Technology's last 12 months net income is $17M. |
| What is the current FCF of Ever Supreme Bio Technology? | Ever Supreme Bio Technology's last 12 months FCF is ($19M). |
| What is Ever Supreme Bio Technology's FCF margin? | Ever Supreme Bio Technology's last 12 months FCF margin is (57%). |
| What is the current EV/FCF multiple of Ever Supreme Bio Technology? | Current FCF multiple of Ever Supreme Bio Technology is (21.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.